PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110γ and p110δ play a major role in the development and progression of PTEN null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using a Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 pathways are aberrantly upregulated, we now demonstrate that the combined activities of 
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease characterized by frequent relapse, resistance to chemotherapy, and reduced survival as compared to Bprecursor ALL (1) . Consistent with most lymphoid malignancies, tumor development and disease progression depend upon deregulation of an oncogene(s) and/or tumor suppressor genes that permit unchecked proliferation and resistance to programmed cell death.
Chromosomal translocations driven by T-cell receptor-regulatory elements occur frequently in T-ALL, resulting in aberrant expression of a select group of transcription factor oncogenes such as TAL1, LMO1, LMO2, TLX1, and TLX3 (2-4). These gene rearrangement events are typically accompanied by constitutive NOTCH1 signaling due to mutations within its heterodimerization (HD) and C-terminal proline-, glutamic acid-, serine-, and threonine-rich (PEST) domains, causing ligand-independent activation and increased stability of the γ-secretase cleaved intracellular domain (ICN1) (5, 6 ).
Subsequent nuclear translocation of ICN1 stimulates transcription of downstream target genes such as HES1, DTX1, and MYC, the latter being an essential mediator of NOTCH1 signaling (7, 8) . cMYC is a known master transcription factor that regulates genes essential for cell metabolism, proliferation and survival (9, 10).
Aberrant activation of the PI3K/AKT pathway has also been implicated in the oncogenic transformation and tumor progression of T-ALL, and is associated with aggressive biological features, drug resistance and poor prognosis (11-13). In the majority of cases this results from a loss or reduced function of the phosphatase and tensin homolog (PTEN) tumor suppressor, which limits levels of PIP3 generated by class I PI3Ks (14) . Interestingly, NOTCH1 has also been reported to indirectly regulate this signaling pathway due to its ability to alter PTEN expression, which has been implicated in inducing GSI resistance in T-ALL by switching "oncogene addiction" (15) . However, other studies have shown that PTEN status does not always correlate with GSI responsiveness, and that NOTCH1 and PI3K/AKT pathways may work in concert to promote tumor growth and survival (16, 17) .
Previously, we have demonstrated the importance of the class I PI3K isoforms p110 γ and p110δ in T cell development and their ability to cooperate as non-classical oncogenes in supporting leukemogenesis in the absence of negative regulation by PTEN (18, 19) . This was further evidenced by our observations that a highly selective dual PI3Kγ/δ inhibitor CAL-130 significantly reduced disease burden, prolonged survival of mice with established PTEN null T-ALL, and induced apoptosis in human T-ALL tumor cells with aberrant PI3K/AKT signaling. Yet, it remains to be determined whether PI3Kγ/ δ regulate transcriptional pathways typically associated with activated NOTCH1 (e.g. cMYC). Investigations along these lines are essential for establishing whether p110-selective small molecule inhibitors could synergize or substitute for GSIs in the treatment of T-ALL. Indeed, the variable antitumor effects of GSIs reported in phase I clinical trails would suggest that such an approach is warranted (20, 21) . To this end, we evaluated the molecular and genetic interplay between these pathways using the Lmo2-driven mouse model of T-ALL where both PI3K/AKT and NOTCH1 are activated (22) (23) .
Additionally, gene set enrichment and pathway analyses were used to determine if these disparate pro-oncogenic pathways controlled similar genes and transcriptional regulators that are determinants of the disease signature associated with T-ALL. , both on C57BL/6J background, were monitored for the onset of leukemia (19, 22, 25) .
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Materials and Methods
Mice
Experiments were performed in accordance with guidelines set forth by the Institutional Animal Care and Use Committee of Columbia University. Animals with established T-ALL received either the dual PI3Kδ/γ inhibitor CAL-130 (10 mg/kg every 8 hours;
Calistoga Pharmaceuticals) (19) or the γ-secretase inhibitor dibenzazepine (DBZ; 10 µmol/kg IP daily; Tocris) (26) for a total of 7 days (27). Kaplan-Meier survival and statistical analyses were performed using GraphPad Prism Version 6.0 software. Values were considered significant at P < 0.05.
Primary leukemia samples and cell lines
Cryopreserved human T-ALL samples were provided by St. Jude Children's Research Hospital and Vanderbilt University Medical Center after appropriate IRB review. All samples were collected with informed consent. Murine CD2-Lmo2 T-ALL cell lines 03007 and 03027 were generated as previously described (23) . In brief, they were generated in the Davé lab (Vanderbilt University) from T-cell leukemia that arose in transgenic B6.CD2-Lmo2 mice. Once established in culture, aliquots of cells were banked in liquid nitrogen and samples obtained for this study in 2014. The cell lines were identified and then confirmed immediately before use by their immunophenotpye and by T-cell receptor Jβ rearrangement (23) .
Retroviral transduction of murine cell line
Plasmid pMSCV-IRES-mCherry and pMSCV-cMyc-IRES-mCherry were kindly provided by the laboratory of Dr. Riccardo Dalla-Favera (Columbia University, NY, NY). Retroviruses were produced in ecotropic packaging cell line 293T Platinum-E according to manufacturer's instructions (Cell Biolabs Inc). Viral transduction was performed using the RetroNectin® (Takara) and spinoculation method as previously described (28).
Mutation detection
Sequencing of the Notch1 and Pten genes was performed on primary mouse T-ALL cells by PCR using Pfu DNA polymerase (Stratagene) with primers specific for exon 34, and exons 3 through 7, respectively.
FACS
Preparation, staining, and detection of cell surface and cytoplasmic proteins in primary T-ALL cells and murine T-ALL cell lines were performed as previously described (19) .
Western blot analysis
Cell lysates were prepared on ice in M-PER Mammalian Protein Extraction reagent (Pierce) containing a cocktail of protease and phosphatase inhibitors (19) . Lysates were subjected to SDS-PAGE, transferred to PVDF membrane (Immobilon-P, Millipore), and membranes probed by overnight incubation (4°C) with appropriate primary antibodies.
7 chemistry (SuperPico West, Pierce).
Drug synergy and cell viability studies
Murine CD2-Lmo2 T-ALL cell lines 03007 and 03027 were plated at optimal density into 384-well tissue culture plates (Greiner 781080) employing the Cell::Explorer automation system (PerkinElmer). CAL-130 or the GSI CompE (ENZO Biochem) (29) (was added using HP D300 Digital Dispenser, and drug activity measured at 60 hours using Cell Titer Glo (Promega). The standard reference model of Bliss independence was employed for the results analysis (30).
Cell lines were also grown in 6 well plates and individually treated with DMSO, CAL-130, IC87114 (Calistoga) (31) CompE for 72 hours. Proliferation and cell death were determined by cell counting with trypan blue and by staining with PI (BD Biosciences) followed by flow cytometric analysis, respectively. For primary murine and human T-ALL samples, cells were harvested from thymi of diseased animals and plated with MS5-DL1 stromal cells in the presence of recombinant IL-7 and FLT-3 (mouse) or recombinant IL-7, FLT-3 and SCF (human). T-ALL cell viability following 72 hours of drug treatment was assessed using the BD Cell Viability kit (BD Biosciences) coupled with fluorescent counting beads as previously described (19) . After 72 hours of treatment, absolute number of cells in DMSO control was set to 100%.
Mitochondria isolation and respiration studies
Mitochondria were isolated from murine T-ALL cells treated with DMSO or CAL-130 (2.5 µM, 12 h) and respiration analyzed in TRIS-MOPS buffer using Clark's type electrode (Hansatech, UK) as described (32) .
OCR measurements
Murine CD2-Lmo2 T-ALL cell lines treated with CAL-130 (2.5µM, 12 h), CompE (1µM, assessed by the decrease in respiration on inhibiting ATP synthase with oligomycin. Cell respiratory control ratio is the ratio of the uncoupled OCR (rate after FCCP injection) to OCR in the presence of oligomycin. Spare respiratory capacity was measured by the ratio of the uncoupled OCR to the basal rate. Experiments were performed using at least 3 biological replicates and all values were internally normalized (33) .
Glucose Uptake Assessment
Murine CD2-Lmo2 T-ALL cell lines cells treated as described were resuspended in glucose-free RPMI-1640 medium containing 1% fetal calf serum (FCS) and 150 µM 2-NBDG (Life Technologies), incubated for 10 min at 37° C, washed with ice-cold PBS and analyzed using flow cytometry. Apigenin (100µM, 30 min treatment), an inhibitor of Glut1 expression, was used as a positive control.
Microarray procedure
A representative murine CD2-Lmo2 derived T-ALL cell line (03007) was treated with DMSO (0.6%) or CAL-130 (2.5 µM; 10 h) or CompE (1 µM; 48 h). Biological triplicates were performed with each experimental condition and gene expression profiling performed by Expression Analysis, Inc. using the Affymetrix Mouse Genome 430 array (#901570). Microarray data were then normalized using the Robust MultiChip Averaging (RMA) algorithm as implemented in the Bioconductor package Affy (34) . A modified t-test was used in Bioconductor Limma package to identify differentially expressed probe sets between each drug treatment group and control group (35) . The Pvalues from Limma analysis were adjusted by Benjamini and Hochberg method to control false discovery rate (FDR) and genes were ranked to identify top 50 up and 50 down regulated genes for each treatment condition (36) .
Statistical analyses
Results are expressed as mean ± SEM for a minimum of 3 independent experiments.
Statistical analysis was performed using either the Student unpaired t-test or two-way ANOVA followed by Bonferroni post-test. P values < 0.05 were considered significant.
Further detailed statistical analysis of the microarray data and information on experimental methods can be found in supplemental materials available on the Molecular Cancer Therapeutics Web site.
Results
Lmo2-driven T-ALL is defined by constitutive activation of PI3K/AKT and
NOTCH1 pathways
Disease penetrance was 100% with a median survival rate of 227 days in CD2-Lmo2 transgenic mice (Fig. 1A) . Tumor cells displayed high levels of both phosphorylated AKT (Thr308 and Ser473) and intracellular NOTCH1 (ICN) with activation of downstream targets (Fig. 1B) ; all tumors expressed the p110γ and p110δ catalytic domains of class I PI3Ks ( Fig. 1 C) . Of note, the majority of Lmo2-driven T-ALL lacked expression of PTEN, acquired Notch1 mutations within the PEST domain (Supplementary Table S1 ) and had evidence of upregulation of the Notch1 target genes such as Deltex1 (~4-fold; Fig. 1D ). Moreover, the majority of circulating blasts had an immunophenotype characteristic of NOTCH1-induced T-ALL in mice: CD8 single positive or CD4/CD8 double positive with high expression of CD25 ( Fig. 2A and B) .
Thus, the CD2-Lmo2 transgenic animal model of T-ALL provided an ideal system to determine whether the combined activities of PI3Kδ/γ regulate similar or distinct oncogenic programs typically associated with NOTCH1 activation.
PI3Kδ/γ blockade or GSI reduces leukemia burden and prolongs survival
To determine the reliance of Lmo2-driven T-ALL on the PI3K/AKT versus NOTCH1 pathway, we treated diseased animals with either the dual PI3Kδ/γ inhibitor CAL-130 (10 mg/kg every 8 hours) or the potent γ-secretase inhibitor DBZ (10 µmol/kg per day) for 7 days. Previously we have shown that CAL-130 is highly selective for the p110γ and p110δ catalytic domains of class I PI3Ks by virtue of its ability to (1) yield an immunologic phenotype similar to that of mice lacking both p110 isoforms when administered to WT animals, and (2) significantly reduces tumor burden and prolong survival in mice that develop PTEN null T-ALL (19) . Despite NOTCH1 activation, all mice had a rapid response to the dual PI3Kδ/γ inhibitor as evidenced by a reduction in circulating blasts and presence of apoptotic cells 4 days post treatment (detected sub-G0 population after propidium iodide (PI) staining) ( Fig. 2A) . Administration of DBZ also reduced disease burden ( In order to investigate the direct effects of PI3K/AKT and NOTCH1 inhibition on tumor cell proliferation and survival, we performed in vitro co-culture of primary leukemic blasts from mice and human T-ALLs using MS5-DL1 stromal cells (19) . Fig. S2 ).
PI3Kδ/γ regulate cMYC expression independently of NOTCH1
NOTCH1 directly regulates cMYC expression, which governs an oncogenic program supporting T-ALL cell growth and survival (7, 8) . Accordingly, CompE blocked NOTCH1 activation in Lmo2-driven T-ALL cell lines and also reduce protein levels of cMYC, albeit at distinct time points (24 hours and 48 hours, respectively) ( Fig. 3D and Supplementary Fig. S1E ). In contrast to the delayed effects associated with GSI, dual inhibition of PI3Kδ/γ activity abolished cMYC protein but not transcript expression within 12 hours of treatment ( Fig. 3D and 3E) . Importantly, CAL-130 was still able to inhibit activation of AKT (phosphorylation of Thr308 and Ser473) and its downstream targets such as glycogen synthase kinase-3β (GSK3β), the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and the ribosomal protein p70 S6 kinase (p70 S6K) (19) , which play a major role in cell cycle progression and tumor cell proliferation ( Fig. 3F and Supplementary Fig. S1F ). Of note, blockade of PI3Kδ/γactivity or GSI abrogated the expression of the anti-apoptotic effectors MCL-1 and phospho-BAD (S136) and lead to upregulation of pro-apoptotic BIM (Supplementary Figs. S3C-F) . In contrast, the majority of effects of CompE were not observed until 48 hours.
In order to confirm that loss of cMYC protein expression is essential for CAL-130 or CompE-induced tumor cell death, we generated an Lmo2-driven murine T-ALL line with constitutive cMYC expression. Indeed, over expression of this oncogene permitted continued tumor cell growth despite incubation with either inhibitor. Moreover, cMYC protein levels remained constant in contrast to cells expressing vector alone (Fig. 4A-F ).
To further demonstrate that down regulation of cMYC is essential for the antitumorigenic effects CAL-130 and that it may exert this effect independent of NOTCH1 activation, we crossed Gt(ROSA)26Sor tm13(CAG-MYC, -CD2*)Rsky /J mice that overexpress cMyc with Lck-cre/Pten (fl/fl) mice that lack Pten. Previously we have shown that T-ALL that develops in PTEN-null mice is exquisitely sensitive to the dual PI3Kγ/δ inhibition (19) .
In contrast, T-ALL with enforced cMYC expression was resistant to CAL-130 treatment (10 mg/kg every 8 hours for 7 days) and showed continued expansion of circulating blasts (Ki67 + /Thy1.2 + population) and lack of PI-staining (Fig. 4G ).
PI3Kδ/γ and NOTCH1 have overlapping gene regulatory networks in Lmo2-driven
T-ALL
To better understand the genetic basis by which PI3Kδ/γ and NOTCH1 regulate tumor progression in Lmo2-driven T-ALL, we generated gene expression signatures based on disease phenotype and drug treatment. (green circle) using a false discovery rate (FDR) of 0.0005 as cut off (Fig. 5A ). Of note, ten-fold more genes were affected following PI3Kδ/γ blockade and included the majority (~62%) of genes altered by GSI monotherapy, a highly significant finding (Fisher's exact test, P < 2.2×10 -16 ). Heat maps were also generated from complete linkage hierarchical cluster analyses of statistically significant changes in gene expression associated with drug treatment versus vehicle control (Fig. 5B ). In the case of PI3Kδ/γ blockade, downregulated genes also included those involved in cMYC-regulated cellular metabolism and/or metabolic reprogramming such as the glycine/serine biosynthetic pathway (e.g. ; Hk2, FDR = 1.68×10 -5 ) and nucleotide metabolism (e.g.
Ak4, FDR=1.66×10 -3 ) (42).
We next defined a murine T-ALL disease signature by ranking all genes based on their differential expression in T-ALL samples compared to wild type murine thymocytes.
To determine the contribution of PI3Kδ/γ and NOTCH1 to the overall disease signature, Table S3 ).
PI3Kγ/δ and NOTCH1 differentially modulate metabolic and mitochondrial pathways in leukemic cells
To better assess the functional categories represented by the set of genes altered in response to the inhibitors, we performed pathway analysis using DAVID (48) . A highly conservative threshold (P < 1x10 -5 ) was used to identify the top down-regulated genes in CAL-130 or CompE treated Lmo2-driven T-ALL cells. In the case of PI3Kδ/γ blockade, there was a significant enrichment in functional categories related to cellular metabolism and most interestingly, pathways that regulate mitochondrial activity ( Fig. 6A and 6B ).
CompE treatment not only altered similar metabolic pathways including those related to carbohydrate, nucleotide, pyruvate and TCA ( Fig. 6C and Supplementary Fig. S4A and   S4B ), but also reduce glucose uptake in T-ALL tumor cells as observed for CAL-130
( Fig. 6D and Supplementary Fig. S5A) ; it did not, however, appear to affect genes that directly regulate mitochondrial function (7, 42, 49) .
As aforementioned, blockade of PI3Kγ/δ activity preferentially altered genes that affect mitochondrial activity, such as those involved in the electron transport chain and oxidative phosphorylation ( 
Discussion
Cumulative evidence indicates that the PI3K/AKT and NOTCH1 pathways not only contribute to the malignant transformation of T cell progenitors but also play a major role in regulating the growth, metabolism, and survival of T-ALL. Here, we explored the interdependence of these oncogenic pathways in promoting tumor cell maintenance, which has profound implications for the development of a rational therapeutic strategy to treat this aggressive hematologic malignancy. It is for this reason that we chose the Previous studies have demonstrated that NOTCH1 can indirectly impact on the activity of the PI3K/AKT pathway by controlling a transcriptional network that regulates PTEN expression in leukemic T cells (15) . Indeed, this mechanism is believed to be responsible for bypassing the requirement for aberrant NOTCH1 signaling that normally supports tumor cell growth and metabolism. In contrast, our studies indicate that NOTCH1 does not regulate PI3Kδ/γ activity or PTEN expression, suggesting that these pathways can function independently of one another. This is exemplified by the lack of correlation between activation status of either pathway and the ability of primary mouse or human T-ALL cells to respond to treatment with CompE or CAL-130. That said, they do appear to control similar oncogenic networks that are indispensible for tumor cell maintenance. Results indicate a genetic underpinning for these observations as evidenced by the considerable overlap in genes regulated by both signaling pathways, including cMYC. The latter was confirmed by the ability of constitutively expressed cMYC to reverse the effects of either inhibitor. Collectively, these data demonstrate that PI3Kδ/γ can support a NOTCH1-independent pathway of cMYC activation in T-ALL, which may account for similar reduction in cell growth and survival but lack of synergistic effect observed in response to CAL-130 and/or CompE (52).
Why then does PI3Kδ/γblockade appear to exert a more rapid and potent anti- Germane to this study is the ability of the PI3K/AKT pathway to act as a master regulator 23 of aerobic glycolysis and cellular biosynthesis that critically relies on mitochondrial bioenergetics (53, 54) . In fact, the shift from oxidative to more glycolytic metabolism is one of the most common changes found in tumor cells. Although our results clearly demonstrated that PI3Kγ/δ blockade or GSI significantly reduce glucose uptake in leukemic cells, only the former was able to rapidly alter mitochondrial function. Indeed, we noted that genes encoding proteins involved in oxidative phosphorylation were uniquely susceptible to CAL-130, including those essential for the mitochondrial respiratory chain complex formation (FDR < 0.005). Consistent with this observation was the robust inhibition of mitochondrial resting and phosphorylating respirations rates. This finding is of particular interest as enhancement in the bioenergetics properties of tumor cells is thought to be a prerequisite for survival.
Overall, our results suggest the existence of a regulatory circuit linking NOTCH1 and PI3K/AKT signaling, with cMYC serving as a crucial node of convergence that intertwines but does preferentially support the activity of either pathway. Moreover, we provide new insights into the mechanism(s) by which the combined activities of PI3Kδ/γ contribute to the maintenance of T-ALL and how pharmacological blockade of these two isoforms exerts a more rapid and pronounced effect on tumor cell proliferation than GSI, yet can yield similar rates of survival of diseased animals. This involves regulating transcriptional pathways and genes typically associated with NOTCH1, as well as distinct an inhibitor of Glut1 expression, was used as a positive control. Data represent mean ± SEM (**, P < 0.01, ***, P < 0.001 relative to DMSO; n = 3, t test). 
